EPCAM and cancer: Eighteen studies of endometrial cancer screening detected a total of 104 cancers among 2688 women (3.9%), diagnosed between at ages 36–72 years (Figure 1).10–27 A total of 1193 of 2688 (44.4%) patients had confirmed mismatch repair/EPCAM mutations and 1495 of 2688 (55.6%) were identified through Amsterdam criteria (Figure 1).